FLUMAZENIL and CONVULSION

Overview

CONVULSION is the #19 most commonly reported adverse reaction for FLUMAZENIL, manufactured by Baxter Healthcare Corporation. There are 29 FDA adverse event reports linking FLUMAZENIL to CONVULSION. This represents approximately 1.3% of all 2,155 adverse event reports for this drug.

Patients taking FLUMAZENIL who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CONVULSION is a less commonly reported adverse event for FLUMAZENIL, but still significant enough to appear in the safety profile.

Other Side Effects of FLUMAZENIL

In addition to convulsion, the following adverse reactions have been reported for FLUMAZENIL:

• INTENTIONAL OVERDOSE — 102 reports
• DRUG INEFFECTIVE — 88 reports
• TOXICITY TO VARIOUS AGENTS — 88 reports
• COMA — 69 reports
• OFF LABEL USE — 69 reports
• INTENTIONAL PRODUCT MISUSE — 61 reports
• DRUG DEPENDENCE — 57 reports
• PRODUCT USE ISSUE — 55 reports
• HYPOTENSION — 54 reports
• DEPRESSED LEVEL OF CONSCIOUSNESS — 52 reports

Other Drugs Associated with CONVULSION

The following drugs have also been linked to convulsion in FDA adverse event reports:

Does FLUMAZENIL cause CONVULSION?

CONVULSION has been reported as an adverse event in 29 FDA reports for FLUMAZENIL. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CONVULSION with FLUMAZENIL?

CONVULSION accounts for approximately 1.3% of all adverse event reports for FLUMAZENIL, making it a notable side effect.

What should I do if I experience CONVULSION while taking FLUMAZENIL?

If you experience convulsion while taking FLUMAZENIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages